Share
Ecouter
News

Glycolytic activity following anti-CD19 CAR-T cell infusion in non-Hodgkin lymphoma


Eur J Clin Invest. 2025 Feb;55(2):e14342. doi: 10.1111/eci.14342. Epub 2024 Nov 1.

https://pubmed.ncbi.nlm.nih.gov/39487603/

Nicolas Vallet  1   2 , Laurianne Drieu Larochelle  1 , Maria-Joao Santiago-Ribeiro  3 , Alban Villate  1 , Martin Eloit  1 , Arnaud Cirée  4 , Laura Zaragoza  5 , Virginie André  5 , Marie Prat-Lepesant  6 , Olivier Hérault  2   7 , Flavie Arbion  8 , Hélène Blasco  9 , Emmanuel Gyan  1   2

Energy metabolism of chimeric antigen receptor-T cells (CAR-T) activation in humans remains unexplored. As a glycolytic activity surrogate, we investigated the dynamics of peripheral blood (PB) lactate in the first weeks post-CAR-T infusion. In 17 patients treated with CD28 harbording anti-CD19 CAR-T for relapsed/refractory non-Hodgkin lymphomas, PB lactate levels increased following CAR-T infusion. Elevated lactate levels correlated with longer CAR-T persistence and higher CD8+/CD4+ ratio. Peripheral blood lactate kinetics may reflect immune cells activation and be useful for bedside monitoring.

more